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ABSTRAK 
 
Ini merupakan satu laporan kes klinikal seorang pesakit yang menghidapi menyakit 
skizofrenia. Biasanya, menggunakan berbagai kombinasi ubat untuk rawatan penyakit 
ini tidak digalakkan, akan tetapi dengan wujudnya ubat-ubatan baru seperti “atypical 
antipsychotic”, cara rawatan sebegini harus dilihat semula. Kes klinikal ini membin-
cangkan penggunaan kombinasi ubat-ubatan untuk rawatan pesakit skizofrenia se-
belum mereka dimulakan dengan ubat clozapine yang merupakan “benteng terakhir 
rawatan”. 
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ABSTRACT  
 
This is a report of a patient on multiple antipsychotic medications for the treatment of 
schizophrenia. Often, polypharmacy is not encouraged, however, with the advent of 
newer atypical antipsychotic agents, this practice may need review. This case will be 
used to highlight the rare instances when polypharmacy may be useful prior to the 
commencement of clozapine for the treatment of schizophrenia.  
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INTRODUCTION  
 
Schizophrenia is the most difficult mental 
illness to define and describe (Gelder et 
al. 2000). The course of illness can be 
poor and life long treatment is needed. 
An early observation by Kreaplin (Henry 
& Smeltzer 2003) noted that 2.5% of pa-
tients with schizophrenia recover fully but 
more recent studies (Kane et al. 1988) 
have been more optimistic quoting 25% 
full recovery. The same study also found 
that 10 -15% of patients with schizophre-
nia do not recover fully. For this group of 
patients, a number of them do not re-
spond to standard treatment using single 
anti-psychotic regime and have been 
coined treatment resistant. Patients who 
are resistant to treatment have only been 
shown to respond to clozapine. Cloza-
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pine however is not without problems, 
among them agranulocytosis can occurs, 
which is a fatal complication that may 
lead to death if not detected and treated 
early. Keeping this fact in mind, is there a 
role for polypharmacy?  
This case will be used to highlight the 
rare instances when polypharmacy may 
be useful prior to the commencement of 
clozapine for the treatment of schizo-
phrenia. 
 
CASE REPORT 
 
A 19 years old college student of Chi-
nese descend presented to our center 
with a week history of aggression and 
irritability. She was also noted to be talk-
ative and there was a history suggestive 
of depressive illness whereby she was 
keeping to herself, crying at times and 
had poor concentration a year before. 
She however had strong persecutory 
delusions of being victimized by the pub-
lic and kept saying that she was publicly 
discriminated against. She also claimed 
to be a special being and able to com-
municate with her boy friend telepa-
thically whom she blamed to be the rea-
son for this. Mentally, she was hostile, 
but her mood was happy. However her 
affect was inappropriate, she had flighty 
ideas and pressure of speech. Her in-
sight was poor. She was initially treated 
for bipolar affective disorder with quetia-
pine 400mg twice daily and a mood sta-
bilizer, and was discharged 15 days later. 
She presented the next day with relapse 
of symptoms when she had suddenly hit 
her father in the car and almost caused a 
motor vehicle accident. During this 
admission her medication was increased 
and she was discharged 9 days later. 
She came for one follow up visit but was 
again admitted two weeks later with 
relapsing symptoms. Her case was dis-
cussed in the postgraduate conference 
and a revised diagnosis of schizophrenia 
was made. On this admission, her psy-
chotic symptoms were more prominent 
with persecutory delusions of discrimina-
tion, thought broadcasting, neologism, 
inappropriate affect and intermittent hos-
tility. Her mood symptoms had all but 
disappeared. She received electrocon-
vulsive therapy during this admission and 
aripiprazole at 10mg daily was started. 
Quetiapine was planned to be tapered off 
slowly. She was discharged 14 days later 
with this combination. During her admis-
sions her biochemical investigations were 
normal, these included full blood test, 
renal and liver function test and fasting 
glucose levels.  
She was followed up in the clinic and 
was compliant to both medication and 
follow up. The quetipaine was reduced 
gradually and her aripiprazole was in-
creased to 15mg once daily. She re-
sponded well to this new regimen until 
she was on aripiprazole 15mg once daily 
and quetiapine 200mg at night. A re-
duction of quetiapine would bring back 
the delusions and any increase would 
make her to become too sedated.  
She has since been maintained on this 
dose and has responded very well. She 
plans to continue her studies for which 
she had stopped for eight months. Her 
family is also very happy with her 
progress. 
 
DISCUSSION 
 
For the pharmacological treatment of 
schizophrenia, monotherapy has always 
been encouraged and advocated in most 
guidelines (Weiden & Casey 1999, APA 
2004). However, polypharmacy has been 
recognized by some and usually sug-
gested as the last resort (Faries et al. 
2005). Among reasons why monotherapy 
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is preferred are to allow psychiatrist to 
accurately evaluate patient’s response to 
the new treatment (Weiden & Casey 
1999) to allow adequate trial of each 
medication, to reduce the complexity of 
the medication regimen, to reduce side 
effects and also to assess and manage 
future symptom exacerbations (Miller & 
Craig 2002).  
The literature has very little evidence 
supporting the use of polypharmacy with 
atypical antipsychotics and is divided on 
its long-term use this way (Stahl & Grady 
2004, Picker et al 2008). Although poly-
pharmacy has been used for a variety of 
reasons with the favorite being to bolster 
medication effectiveness in treating pa-
tients with refractory psychotic symp-
toms, mood symptoms or behavioral 
problems, the risk of combining two 
atypical antipsychotic appears to out-
weigh the benefits (Stahl & Grady 2004). 
Among these risk is a potentially higher 
mortality and an increase in metabolic 
problems (Faries et al. 2005, Stahl 2004). 
For our patient, polypharmacy appears 
to work well for her. It has given her an 
option to recover fully. It has also saved 
her the option of treatment with clozapine 
which was impending in view of her poor 
response to quetiapine and aripiprazole 
at high doses individually. Although clo-
zapine has been proven for difficult cases 
like our patient, the side effects and 
regular blood monitoring may be 
cumbersome given other options in 
treatment. The use of aripiprazole which 
is claimed to be weight neutral and less 
sedating (Lieberman 2004) is better 
suited for a young and active individual 
and will hopefully encourage compliance. 
Although the combination of aripiprazole 
and quetiapine has not been studied in 
detail, her low dose of quetiapine at night 
may be useful for sleep as it is more se-
dating but may not be sufficient to cause 
weight gain as a side effect.  
Another explanation which may explain 
her response to this combination could 
well be that she had improved on the 
dose of aripiprazole 15mg which she has 
been taking for more than 3 months. The 
relapse of symptoms when quetiapine 
was titrated down and when ariprazole 
was increased could well be due to aka-
thesia, or inner restlessness, which is a 
known side effect in the initial stages. It 
can be very discomforting to the patient 
and may lead her to have a persecutory 
type of delusion. 
Whichever the explanation, in the end it 
is all about the patient and her recovery 
that matters most. 
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